VTGN - VistaGen Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4350
+0.0048 (+1.12%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.4302
Open0.4442
Bid0.0000 x 1800
Ask0.8000 x 2200
Day's Range0.4208 - 0.4500
52 Week Range0.2900 - 1.8600
Volume144,163
Avg. Volume477,264
Market Cap18.802M
Beta (3Y Monthly)-0.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
    PR Newswire

    VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline results from the ELEVATE study, a Phase 2 study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive treatment of major depressive disorder (MDD). In this study, the AV-101 treatment arm did not differentiate from placebo on the primary endpoint (change in the Montgomery-Åsberg Depression Rating Scale (MADRS-10) total score compared to baseline). As in prior clinical studies, AV-101 was well tolerated, with no psychotomimetic side effects or serious adverse events.

  • VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
    PR Newswire

    VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview

    SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system ...

  • VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
    PR Newswire

    VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease

    SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ -- VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the European Patent Office (EPO) has granted the Company a second patent for therapeutic uses of AV-101, its oral NMDA (N-methyl-D-aspartate) receptor glycine site antagonist. The new patent expands the set of claims relating to treatment of depression and dyskinesia (involuntary or diminished voluntary muscle movements) associated with levodopa therapy for Parkinson's disease. AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA receptor modulators.

  • VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
    PR Newswire

    VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder

    SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ -- VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, announced today that the last patient has completed dosing in the ELEVATE Phase 2 clinical study of AV-101, the Company's novel, oral NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive (add-on) treatment with an FDA-approved oral antidepressant for major depressive disorder (MDD). The Company remains on track to report top line results of the ELEVATE study before the end of 2019.

  • ACCESSWIRE

    VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder

    Company on Track to Report Topline Data Before Year End SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 15, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing ...

  • ACCESSWIRE

    VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) ...

  • ACCESSWIRE

    VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2019 / VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,322,138 related to methods of treating major depressive disorder (MDD) with VistaGen’s PH10 neuroactive nasal spray, a potential first-in-class, neurosteroid administered in microgram doses for treatment of MDD. The newly granted patent will not expire until at least 2034.

  • ACCESSWIRE

    VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 25, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) ...

  • ACCESSWIRE

    VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2019 / VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company committed to developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced positive results of recent preclinical studies of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a widely-used MPTP non-human primate model for reproducing motor complications of Parkinson's disease (PD), including dyskinesia (sudden uncontrolled movements) observed in PD patients treated with levodopa. In the MPTP primate model, AV-101's antidyskinetic effects were similar to those generally observed with amantadine therapy, but AV-101 did not cause adverse effects experienced with amantadine.

  • ACCESSWIRE

    VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 / VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced positive results of recent preclinical studies of the effects of AV-101, VistaGen's oral NMDA receptor glycine site antagonist, compared to pregabalin (Lyrica®1) in the Chung ligation model of pain, an accepted gold standard preclinical model for chronic neuropathic pain caused by nerve damage.

  • ACCESSWIRE

    VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety ...

  • ACCESSWIRE

    VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 2, 2019 / VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced top line results from an exploratory Phase 2 clinical study of AV-101 as a monotherapy (which is treatment without a concurrent FDA-approved antidepressant) in patients with treatment-resistant depression (TRD). In the 19-patient study sponsored and conducted by the U.S National Institute of Mental Health (NIMH), AV-101 did not demonstrate significant separation from placebo on the primary outcome measure, the change from baseline in the Hamilton Depression Rating Scale (HDRS) total score compared to placebo.

  • ACCESSWIRE

    VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central ...

  • ACCESSWIRE

    Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2019 / VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, announced today additional results from a positive pilot Phase 3 study of PH94B, a potential first-in-class neuroactive nasal spray shown to be effective on an as-needed (PRN) basis for treatment of social anxiety disorder (SAD). The new data were presented in a poster session at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference in Chicago. In the 22-patient, four-week, randomized, double blind, placebo-controlled pilot Phase 3 crossover study, subjects receiving PH94B had a significantly greater decrease in average peak Subjective Units of Distress scores compared to placebo within one week of treatment.1 There was also a significantly greater decrease in Liebowitz Social Anxiety Scale (LSAS) avoidance scores for subjects who received PH94B first, before crossing over to placebo.

  • ACCESSWIRE

    VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety ...

  • ACCESSWIRE

    VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central ...

  • ACCESSWIRE

    VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central ...

  • ACCESSWIRE

    VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019

    SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety ...

  • ACCESSWIRE

    Four Tech Stocks Looking To Test February Highs

    ParcelPal Technology Inc (PTNYF) (PKG), Citius Pharmaceuticals Inc(CTXR), VistaGen Therapeutics Inc (VTGN), and Frontier Communications Corporation (FTR) represent 4 tech stocks on the rise on Wednesday. The Company recognized an issue within the consumer marketplace: food delivery apps existed, but that was all we could order. Seizing the opportunity, ParcelPal created an on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.

  • GlobeNewswire

    VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

    VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $1.00 per share. In addition, VistaGen granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. VistaGen currently intends to use the net proceeds from the offering for continued development of its CNS pipeline programs, and for general research and development, working capital and general corporate purposes.

  • GlobeNewswire

    VistaGen Therapeutics Announces Proposed Public Offering of Common Stock

    VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All securities to be sold in the offering are to be sold by VistaGen. In addition, VistaGen intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

  • GlobeNewswire

    VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia

    VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that the Japan Patent Office (JPO) has issued a patent related to methods of treating depression with AV-101, VistaGen’s oral NMDA receptor glycine site antagonist in Phase 2 development for treatment of major depressive disorder (JP 6436913B). The new AV-101 Japanese patent will not expire until at least 2034. “Development and commercialization of our CNS pipeline in Japan, together with the U.S., China and the European Union, is among our top corporate priorities, stated Shawn Singh, Chief Executive Officer.

  • GlobeNewswire

    VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10

    VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent related to methods of treating depression with PH10, VistaGen’s investigational new generation CNS nasal spray in Phase 2 development for major depressive disorder (MDD). In a small exploratory Phase 2a clinical study, at microgram doses, PH10 nasal spray was observed to have rapid-onset antidepressant effects, without systemic exposure, psychological side effects or safety concerns.

  • GlobeNewswire

    VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for.

  • GlobeNewswire

    VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central.